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A B S T R A C T
Purpose
To analyze the effect of different doses of paclitaxel with fixed doses of carboplatin in the treatment of
ovarian cancer.
Patients and Methods
Patients with histologically confirmed epithelial ovarian cancer, International Federation of Gynecology
and Obstetrics stages IIB to IV, were eligible for this randomized, multicenter study. Women were
randomly assigned to treatment with (1) carboplatin at the dose (in milligrams) corresponding to the
following formula: target area under the free carboplatin plasma concentration versus time curve (AUC)
 6  (glomerular filtration rate  25) mg/m2 (AUC6) plus paclitaxel 175 mg/m2 for six cycles every 21
days or (2) carboplatin AUC6 plus paclitaxel 225 mg/m2 for six cycles every 21 days. A total of 502
women entered the study.
Results
Pathologic complete response was documented in 132 patients (63.8%) in the 175 mg/m2 group and in
127 cases (55.7%) in the 225 mg/m2 group (2 P  .090). The 4-year progression-free survival rate was
41.5% (SE  3.5) in the 175-mg group and 39.2% (SE  3.5) in the 225-mg group. The corresponding
4-year survival rates were 46.2% (based on 115 deaths) and 47.3% (based on 113 deaths), respectively.
Conclusion
This randomized trial suggests that paclitaxel 175 mg/m2 plus carboplatin AUC6 is the schedule with a
more favorable profile than paclitaxel 225 mg/m2 plus carboplatin AUC6.
J Clin Oncol 22:686-690. © 2004 by American Society of Clinical Oncology
INTRODUCTION
Cisplatinum plus paclitaxel is considered an
optimal chemotherapy for treatment of ad-
vanced ovarian cancer [1-3]. Recently the
combination of carboplatin and paclitaxel
has been shown to have equal efficacy with
less toxicity [4-6]. Common doses are pacli-
taxel 175 mg/m2 and target area under the
free carboplatin plasma concentration ver-
sus time curve (AUC) of 5 to 6 [6].
Data are scanty on the role of escalating
doses of paclitaxel in combination with car-
boplatin at fixed doses [7-10]. Ten Bokkel
Huinink et al [7] performed a pilot study
with 46 patients to evaluate the combination
with two doses of paclitaxel (125 and 200
mg/m2) and carboplatin (300 and 600 mg/
m2); the overall response rate was 61% and
was higher with the larger dose of paclitaxel.
Bolis et al [8] reported preliminary re-
sults of a phase I trial using a dose escalation
of paclitaxel (150 to 250 mg/m2) with a fixed
dose of carboplatin (300 mg/m2). The over-
all response rate was 86% in patients treated
with 200 mg/m2 of paclitaxel and 74% in
those treated with 225 mg/m2.
To analyze the effect of different doses
of paclitaxel combined with fixed doses of
carboplatin in the treatment of ovarian can-
cer, we conducted a large, randomized, clin-
ical trial [11]. In this trial, carboplatin was
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given before paclitaxel following our previous experience
showing no sequence-dependent effect on toxicity [8].
PATIENTS AND METHODS
Entry criteria for this randomized, multicenter study were as fol-
lows: histologically confirmed epithelial ovarian cancer (Interna-
tional Federation of Gynecology and Obstetrics [FIGO] stages IIB
to IV); Eastern Cooperative Oncology Group performance status
 2; age less than 80 years; no history of other malignant diseases;
no previous chemotherapy or radiotherapy; adequate hemato-
logic, renal, hepatic, and cardiac functions as defined by absolute
neutrophil count (ANC)  1.5  10/L, platelet count  100 
10/L, total bilirubin  1.25 times the upper normal limit, creati-
nine 1.5 times the upper normal limit, and no noteworthy ECG
abnormalities. Brenner tumors and borderline, low-potential
(grade 0) tumors were not included.
Within 28 days of cytoreductive surgery, eligible women were
randomly assigned to treatment with (1) carboplatin at the dose
(in milligrams) corresponding to the following formula: target
AUC 6 [glomerular filtration rate 25] mg/m2 (AUC6) plus
paclitaxel 175 mg/m2 for six cycles every 21 days or (2) carboplatin
AUC6 plus paclitaxel 225 mg/m2 for six cycles every 21 days.
Randomization by phone was centralized. Separate random-
ization lists were used for each participating center and residual
tumor after first-line surgery.
The glomerular filtration rate was calculated by the Cockcroft
formula [12]. The dose corresponding to the AUC6 of carboplatin
was administered in 30 minutes, without premedication diluted in
250 mL of D5W or normal saline.
All patients were then premedicated to prevent allergic reactions
with chlorpheniramine 10 mg administered intramuscularly 1 hour
before paclitaxel, hydrocortisone 500 mg administered intravenously
30 minutes before paclitaxel, and cimetidine 300 mg administered
intravenously 30 minutes before paclitaxel, which was diluted in
1,000 mL of D5W. Only glass or polyolefin containers and polyethyl-
ene-lined nitroglycerin tubing are recommended for drug adminis-
tration. Polyvinylchloride infusion sets were not used. Infusion time
was 180 minutes for paclitaxel and 30 minutes for carboplatin.
Weekly counts were made in both treatment arms during
each cycle of therapy to determine nadir counts and duration of
toxicity. Other toxicities were recorded according to WHO
recommendations [13].
Dose Reduction
Carboplatin was reduced for hematologic toxicity, and pac-
litaxel was reduced for hematologic and nonhematologic toxicity.
The paclitaxel dose was reduced when neutropenia or thrombo-
cytopenia (see Evaluation of Response) were present for 7 days or
more (ie, two consecutive counts 1 week apart) or in case of febrile
neutropenia with or without documented infection. The dose was
reduced to 150 or 200 mg/m2, respectively, if the ANC was be-
tween 1,000 and 1,500 109/L and the platelet count was between
50 and 100 109/L at nadir, and to 135 and 175 mg/m2 if the ANC
was between 500 and 1,000109/L or if the platelet count was less
than 50 109/L. In the same cases, the carboplatin dose was also
reduced to AUC5 or AUC4, as clinically indicated. Treatment was
delayed for a maximum of 2 weeks if the ANC was less than 1,500
 109/L or platelet count was less than 100 109/L at the sched-
uled time of the next cycle.
In case of grade 3 gastrointestinal toxicity according the
WHO classification or grade 1 to 2 neurologic toxicity, the dose
of paclitaxel was reduced by 25 or 50 mg/m2 as clinically
indicated. In case of grade 3 to 4 neurologic or cardiac toxicity,
treatment was stopped.
Evaluation of Response
After three cycles of treatment, patients were examined clin-
ically, CA-125 was assayed, and the disease was reassessed by
ultrasonography or computed tomography, as appropriate. An
increase in CA-125 with no evidence of progression of the disease
was not considered evidence of progression. If progression was
observed, the patient was withdrawn from the study.
At the end of treatment, response was assessed as follows:
clinical complete response (CR) was defined as complete disap-
pearance of all clinically detectable tumor and negative CA-125 for
at least two assays not less than 4 weeks apart. Pathologic CR was
defined as disappearance of the disease at histologic examination
assessed by at least eight random biopsies, with negative peritoneal
cytology during second-look laparotomy or laparoscopy. Second-
look surgery was not mandatory. Patients with no clinically or
instrumentally measurable disease at randomization and those
who did not undergo second-look surgery were included in the
analysis for survival but not in the evaluation of response.
No specific instructions were given for management of pa-
tients after the study treatment or in case of discontinuation.
However, the general policy of participating centers included sec-
ond-line chemotherapy with a platinum-based compound in case
of late recurrence or progression of disease (ie,12 months after
first-line treatment) and a scheme including anthracyclines in case
of early recurrence/progression.
Before randomization, we recorded each patient’s name, age,
performance status, and FIGO stage. Other data were collected
prospectively during the trial. Progression-free and survival status
for each patient was reported to the coordinating center yearly.
The research protocol was approved independently by the ethics
committees of the individual centers, which established the pro-
cedures for obtaining informed consent.
A total of 502 women were randomly assigned. Of these, eight
patients were not eligible (four because of age, two because of
Eastern Cooperative Oncology Group performance status of 3,
and two because of unknown FIGO stage) and were excluded from
the analysis. Thus the present study is based on 244 women in the
paclitaxel 175-mg/m2 arm and 250 women in the 225-mg/m2 arm.
The patients were recruited in 11 centers (mean number of pa-
tients randomized per center, 45 patients; range, seven to 145
patients) from June 1993 to July 2000, with an average monthly
randomization rate of 5.7 (range, 1 to 20).
Respectively, three (1.3%) and seven (2.8%) women in the
175-mg/m2 and 225-mg/m2 groups were lost to follow-up. They
were considered in the analysis for the period during which they
were in the trial.
Statistical Analysis
Survival was the end point for the main analysis of treatment
effect, and survival was calculated from date of randomization to
date of death (of any cause) or censored to the last follow-up date
if no death occurred. Follow-up was updated in November 2000
for the majority of patients. Progression-free survival was calcu-
lated from the date of randomization to the date of clinical or
pathologic progression or death, whichever came first.
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Analysis was based on the intention-to-treat principle; in
other words, patients remained in the allocated group regardless of
whether the treatment assigned was given. Survival probabilities
were estimated according to the Kaplan-Meier method and com-
pared by the log-rank test [14,15].
The Cox model was fitted to the data after graphically
checking the proportional hazards assumption to adjust the
estimate of treatment effect and to assess the prognostic value
of residual tumor size after first surgery, FIGO grade, stage, and
histotype [16]. The Pearson 2 test for association was applied
to test the relationship between treatment and response and to
compare the impact of different types of toxicity in the two
arms, when applicable.
Considering a 30% 4-year baseline survival, this study had
80% power to show a 10% absolute difference between the two
arms, with a two-tailed log-rank test and alpha 0.05 [17].
RESULTS
Table 1 shows the distribution of patients according to
baseline characteristics. The two groups were similar in
terms of baseline characteristics. For example, the median
age was the same in both groups, and the proportion of
stage IIIc was 71.2% in the 175-mg/m2 paclitaxel group and
72% in the 225-mg/m2 group. Likewise, the two groups had
similar proportions of serous or mucinous histotype
(67.2% and 64.7%), grade 1 to 2 cases (20.0% and 18.6%),
residual tumor after first surgery greater than 1 cm (52.9%
and 53.2%), and positive lymph nodes (53.1% and 54.1%).
Second-look surgery was performed in 79 cases in the
175-mg/m2 group and in 67 cases in the 225-mg/m2 group.
No difference emerged in response to treatment (Table 2).
CR was documented in 132 patients (pathologic in 70 pa-
tients) in the 175-mg/m2 group and 127 patients (patho-
logic in 61 patients) in the 225-mg/m2 group. Progression
was observed in similar proportions in the two dosage arms.
Analysis in strata of residual disease showed no differ-
ence in the response for women with residual tumor  1
cm, greater than 1 cm, or carcinosis.
The median follow-up was 54 months in the 175-mg/m2
group and 47 in the 225-mg/m2 group. The 4-year progres-
sion-free survival rates were 41.5% (SE 3.5) and 39.2% (SE
 3.5), respectively (log-rank test 2 0.033; P .856). The
corresponding 4-year survival figures were 46.2% (based on
115 deaths) and 47.3% (based on 113 deaths; log-rank test 2
 0.125; P .724; Fig 1). The 4-year survival rates were also
largely similar in cases with residual tumor1 cm (70.5% and
65.0%) or greater than 1 cm or carcinosis (33.0% and 37.1%).
The Cox model analysis (including terms for age, residual
tumor, stage, histotype, and lymph node involvement) largely
confirmed these findings, with the odds ratio of 4-year survival
being 0.9 (95% CI, 0.7 to 1.3) for women given 225 mg/m2
compared with women given 175 mg/m2 of paclitaxel.
Table 1. Baseline Characteristics of Study Patients
Paclitaxel Dose
175 mg/m2 225 mg/m2
No. % No. %
Age, years
Median 58 58
Range 13-78 27-77
Stage
IIb 6 2.5 9 3.6
IIc 11 4.5 11 4.4
IIIa 6 2.5 3 1.2
IIIb 37 15.2 44 17.6
IIIc 175 71.2 180 72.0
IV 9 3.7 3 1.2
Histotype
Serous 147 61.0 159 63.9
Mucinous 15 6.2 2 0.8
Endometrioid 32 13.3 27 10.8
Clear cell 40 16.6 51 20.5
Mixed 7 2.9 10 4.0
Grade
1 9 3.8 6 2.4
2 39 16.2 40 16.2
3 188 78.3 198 80.2
4 4 1.7 3 1.2
Lymph nodes
Positive 76 53.1 72 54.1
Negative 67 46.9 61 45.9
Residual tumor
1 cm 88 36.4 90 36.3
1 cm 128 52.9 132 53.2
Carcinosis 26 10.7 26 10.5
NOTE. In some cases, the sum does not add up to the total because of
missing values.
Table 2. Response According to Treatment Group
Paclitaxel Dose
P (2)
175 mg/m2 225 mg/m2
No. % No. %
Total series .090
CR 132 63.8 127 55.7
PR/NC 56 27.0 84 36.8
PD 19 9.2 17 7.5
Residual tumor  1 cm .288
CR 63 78.8 57 67.9
PR/NC 13 16.2 21 25.0
PD 4 5.0 6 7.1
Residual tumor  1 cm .106
CR 61 58.1 58 48.7
PR/NC 31 29.5 51 42.9
PD 13 12.4 10 8.4
Carcinosis .697
CR 8 36.4 11 45.8
PR/NC 12 54.5 12 50.0
PD 2 9.1 1 4.2
NOTE. Data do not add up to the total because of missing values.
Furthermore, in some patients, data were not available because of short
follow-up.
Abbreviations: CR, complete response; PR, partial response; NC, no
change; PD, progressive disease.
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The planned cycles were given to 207 of the women
allocated to 175 mg/m2 of paclitaxel and 219 of the women
allocated to 225 mg/m2. The dose of paclitaxel, carboplatin,
or both was reduced in 59 women allocated to 175 mg/m2
and in 91 women allocated to 225 mg/m2. The scheduled
doses without any delay were given to 170 patients in the
175-mg/m2 group and to 162 patients in the 225-mg/m2
group. Doses of carboplatin were reduced in 33 cases in the
175-mg/m2 group and in 27 cases in the 225-mg/m2 group.
A delay in dose delivering was observed in 23 cases in the
175-mg/m2 group and in 42 cases in the 225-mg/m2 group.
We analyzed the 4-year survival in women who re-
ceived the planned doses without any delay, and no differ-
ence emerged between the two groups (P  .05). Table 3
shows the reported toxicities: no real difference emerged in
the frequency of toxicities in the two groups, except for
alopecia, which was more frequent in the 175-mg/m2 pac-
litaxel group, and neurotoxicity, which was more frequent
in the 225-mg/m2 paclitaxel group.
Thrombocytopenia grade 3 to 4 was reported in 40
cases in the 175-mg/m2 group and in 49 cases in the 225-
mg/m2 group; this difference was not statistically signifi-
cant. The mean cycle in which grade 3 to 4 thrombocytope-
nia was observed was similar in the two groups (5.6 cycle in
the 175-mg/m2 group and 5.8 in the 225-mg/m2 group).
DISCUSSION
This study found no substantial difference in response and
survival between women treated with 175 mg/m2 or 225 mg/m2
of paclitaxel with carboplatin given to AUC6. However, neu-
rotoxicity was more frequent in the higher dose group.
Published studies on the doses and dose-intensity of
paclitaxel in the treatment of ovarian cancer are few and
controversial. In a bifactorial design trial, 407 patients with
Fig 1. Survival according to study group.
Table 3. Toxicity
Paclitaxel Dose
P (2)
175 mg/m2 225 mg/m2
No. % No. %
Allergic reaction .754
Yes 11 4.8 10 4.2
No 220 95.2 230 95.8
Neutropenia grade .243
0 42 18.0 37 15.3
1 16 6.9 24 10.0
2 40 17.2 27 11.2
3 70 30.0 81 33.6
4 65 27.9 72 29.9
Thrombocytopenia grade .391
0 96 41.2 112 46.7
1 48 20.6 42 17.5
2 49 21.0 37 15.4
3 31 13.3 38 15.8
4 9 3.9 11 4.6
Anemia grade .050
0 34 14.5 56 23.2
1 82 35.0 68 28.2
2 73 31.2 76 31.6
3 43 18.4 35 14.5
4 2 0.9 6 2.5
Alopecia grade .010
0 36 15.4 61 25.3
1 1 0.4 1 0.4
2 6 2.6 1 0.4
3 188 80.3 178 73.9
4 3 1.3 0 —
Mucositis grade .507
0 218 92.8 226 93.8
1 17 7.2 14 5.8
2 — — 1 0.4
Nausea and vomiting grade .194
0 85 36.2 107 44.4
1 98 41.7 87 36.1
2 45 19.1 44 18.3
3 7 3.0 3 1.2
Myalgia grade .743
0 140 59.6 143 59.3
1 78 33.2 78 32.4
2 15 6.4 15 6.2
3 2 0.8 5 2.1
Neurotoxicity grade .001
0 81 34.5 63 26.0
1 121 51.5 94 38.9
2 31 13.2 70 28.9
3 2 0.8 15 6.2
Cardiotoxicity grade .490
0 221 94.0 229 95.0
1 14 6.0 11 4.6
2 — — 1 0.4
NOTE. The sum does not add up to the total because of missing values.
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recurrent ovarian cancer were randomly assigned to one of
two doses of paclitaxel (135 or 175 mg/m2) and to one of
two schedules (3 or 24 hours) after a standard regimen to
prevent allergic reactions. Arthralgia/myalgia syndrome
and peripheral neuropathy were more common in the
higher dose arms. No significant difference emerged in
clinical response [18].
In a small phase II trial of patients with relapsing ovar-
ian cancer, the response rate seemed to increase with the
dose, but the finding was based on a small number of
patients [7]. The present study confirms the lack of differ-
ence in clinical response with low- or high-dose paclitaxel,
in combination with carboplatin AUC6, in never-treated
ovarian cancer.
In interpreting this finding, we have to take into ac-
count the limitations of the study. First, our study was
powered to identify only a difference of 10% or more for
4-year survival. However, it is interesting to note the lower
rate of response in women treated with the higher dose.
Another limitation is the fact that the overall differ-
ences in doses given to the two groups are not marked. We
randomly assigned patients to receive 175 mg/m2 of pacli-
taxel with carboplatin AUC6 or 225 mg/m2 of paclitaxel, a
dose less than 30% higher than the lower one. However,
toxicity makes it impossible to give higher doses.
With regard to toxicity, the two schedules were gener-
ally safe. Toxicities grade 3 or 4, except for alopecia, were
reported in approximately 35% in both groups. However,
there was markedly more neurotoxicity in women treated
with 225 mg/m2 of paclitaxel. This is consistent with the Ten
Bokkel Huinink findings and with a small phase II trial [8].
In the latter, there was no grade 2 to 3 neurotoxicity in 12
women treated with paclitaxel less than 200 mg/m2 plus
carboplatin 320 mg/m2, but this incidence was 40% in 85
women treated with paclitaxel 225 mg/m2 plus carbopla-
tin 300 mg/m2.
We found a higher frequency (statistically significant)
of alopecia in patients treated with 175 mg/m2 of paclitaxel.
However, the difference in clinical terms was limited: in
fact, only three cases with alopecia grade 4 were observed in
the 175-mg/m2 group.
In conclusion, this large, randomized trial suggests that
paclitaxel 175 mg/m2 plus carboplatin AUC6 is a more
favorable schedule than paclitaxel 225 mg/m2 plus carbo-
platin AUC6. Small differences in clinical response cannot
be excluded on the basis of the present findings, but consid-
ering the higher frequency of neurotoxicity in the paclitaxel
225-mg/m2 arm, the dose of 175 mg/m2 should be consid-
ered the first choice. With an eye to the development of
combination schedules, it is worth noting that paclitaxel
does not seem to show dose-related efficacy.
  
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